Projects
NOVEL THERAPY FOR BRAIN METASTASIS KU Leuven
Despite research advances, cancer still remains a major life threat with increasing societal burdens. Previously, the theragnostic laboratory at KU Leuven has developed an ingenious small molecule dual targeting pan-anticancer theragnostic strategy called OncoCiDia, which combines tumor necrotizing effect by using a vascular disrupting agent such as Combretastatin A-4 phosphate (CA4P) and targeted radiotherapy by using a necrosis-avid ...
Optimization of a new targeted radiotherapy to improve treatability of cancer. KU Leuven
Cancer still remains a life-threatening disease, with limited curative options. OncoCiDia is a novel, generic anticancer strategy with great potential for about 80% of all malignant tumors. The principle is as follows: the tumor(s) are first attacked by a drug that specifically destroys the blood vessels of the tumors. This causes central necrosis, killing the majority of the tumor cells. The outside of the tumor, which can escape because it ...
Promoting active ageing: functional nanostructures for alzheimer's disease at ultra-early stages KU Leuven
Alzheimer’s disease (AD) is the leading cause of dementia and loss of autonomy in the elderly, implying a progressive cognitive decline and limitation of social activities. Progressive aging of EU population will increase the magnitude of this problem in the next decades. Currently, there is not an effective method for the early diagnosis of AD. Therefore, there is an urgent need to develop new effective early diagnostic and therapeutic ...